These findings suggest that LSD1 inhibition would be most effective against neuroendocrine-high subtypes of SCLC, especially SCLC-A, consistent with the observation that more mesenchymal-like SCLC cells are resistant to LSD1 inhibition [224]. The gene discussed is KDM1A; the disease is small cell lung carcinoma.